Ironwood Pharmaceuticals Inc expected to post earnings of 8 cents a share - Earnings Preview

Ironwood Pharmaceuticals

18/02/2025 13:33

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a fall in quarterly revenue when it reports  results on
February 18 (estimated) for the period ending December 31 2024
    * The Boston Massachusetts-based  company is expected to
report a
20.2% decrease in revenue to $93.821 million from $117.55
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ironwood Pharmaceuticals
Inc
is for earnings of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $7.50​, above​ its last closing price
of $1.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  0.06        0.08       0.02      Missed  -75.2
 Jun. 30 2024  0.13        0.15       0.00      Missed  -100
 Mar. 31 2024  0.15        0.19       -0.02     Missed  -110.5
                                                        ​
 Dec. 31 2023  0.21        0.21       -0.01     Missed  -104.9
 ​​Sep.        0.17        0.16       0.09      Missed  -42.9
 30 2023                                                
 Jun. 30 2023  0.26        0.25       0.31      Beat    25.7​
 Mar. 31 2023  0.23        0.24       0.25      Beat    3.1
 Dec. 31 2022  0.26        0.27       0.27      Met     0
 This summary was machine generated February 18 at 13:33 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)